MX9702732A - Uso de derivados de indol para el tratamiento de diferentes enfermedades. - Google Patents

Uso de derivados de indol para el tratamiento de diferentes enfermedades.

Info

Publication number
MX9702732A
MX9702732A MX9702732A MX9702732A MX9702732A MX 9702732 A MX9702732 A MX 9702732A MX 9702732 A MX9702732 A MX 9702732A MX 9702732 A MX9702732 A MX 9702732A MX 9702732 A MX9702732 A MX 9702732A
Authority
MX
Mexico
Prior art keywords
headache
glaucoma
allergic
arthritis
treatment
Prior art date
Application number
MX9702732A
Other languages
English (en)
Other versions
MXPA97002732A (es
Inventor
Paul Gupta
Juan Lahuerta
Shirley Jones
Susan Frances Robson
Gillian Mary Ryder Samuels
Alan Brian Wilson
Martin James Wythes
Kathryn Louise Monkhouse
Gillian Christine Land
Original Assignee
Pfizer Res & Dev
Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev, Sa filed Critical Pfizer Res & Dev
Publication of MXPA97002732A publication Critical patent/MXPA97002732A/es
Publication of MX9702732A publication Critical patent/MX9702732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion provee el uso de un compuesto de formula I en donde R1 y R2 representan independientemente H o alquilo de C1-C6 o una sal farmacéuticamente aceptable del mismo, en la fabricacion de un medicamento para el tratamiento de trastornos dermatologicos; neuropatía periféricas; artritis; enfermedades gastrointestinales o urogenitales; dolor de cabeza asociado con substancias o abstinencia; dolor de cabeza por tension; migraña pediátrica; cefalgia disautonoma postraumática; dolor orofacial; enfermedades alérgicas o cronicas obstructivas de las vías respiratorias; glaucoma o inflamacion ocular; o profilaxis de migraña.
MX9702732A 1994-10-12 1995-10-05 Uso de derivados de indol para el tratamiento de diferentes enfermedades. MX9702732A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9420529A GB9420529D0 (en) 1994-10-12 1994-10-12 Indoles
GB9420529.1 1994-10-12
PCT/EP1995/003965 WO1996011685A2 (en) 1994-10-12 1995-10-05 Use of indole derivatives for the treatment of various diseases

Publications (2)

Publication Number Publication Date
MXPA97002732A MXPA97002732A (es) 1997-06-01
MX9702732A true MX9702732A (es) 1997-06-28

Family

ID=10762708

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702732A MX9702732A (es) 1994-10-12 1995-10-05 Uso de derivados de indol para el tratamiento de diferentes enfermedades.

Country Status (25)

Country Link
US (2) US6455567B1 (es)
EP (1) EP0785781B1 (es)
JP (2) JP3096306B2 (es)
KR (1) KR970705992A (es)
CN (1) CN1160347A (es)
AT (1) ATE210980T1 (es)
AU (1) AU3699795A (es)
BR (1) BR9504375A (es)
CA (1) CA2202484C (es)
CO (1) CO4480025A1 (es)
CZ (1) CZ285633B6 (es)
DE (1) DE69524780T2 (es)
DK (1) DK0785781T3 (es)
ES (1) ES2167465T3 (es)
FI (1) FI971527A0 (es)
GB (1) GB9420529D0 (es)
HU (1) HUT77317A (es)
IL (1) IL115530A (es)
MX (1) MX9702732A (es)
NO (1) NO971606D0 (es)
PE (1) PE47296A1 (es)
PL (1) PL319868A1 (es)
PT (1) PT785781E (es)
WO (1) WO1996011685A2 (es)
ZA (1) ZA958557B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis
AU771130B2 (en) * 2000-01-18 2004-03-11 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1307191A2 (en) * 2000-07-28 2003-05-07 Inspire Pharmaceuticals, Inc. Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
ES2172415B2 (es) 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
EP1452167A1 (de) * 2003-02-28 2004-09-01 Cognis France S.A. Kosmetische, pharmazeutische und/oder dermatologische Zubereitungen enthaltend einen Extrakt aus Eperua falcata
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
DE10337184A1 (de) * 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US9789161B2 (en) * 2006-04-28 2017-10-17 Warsaw Orthopedic, Inc. Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
US8916611B2 (en) * 2006-04-28 2014-12-23 Warsaw Orthopedic, Inc. Pharmaceutical removal of neuronal extensions from a degenerating disc
US20070253960A1 (en) * 2006-04-28 2007-11-01 Josee Roy Pharmaceutical removal of vascular extensions from a degenerating disc
CN103479624B (zh) * 2013-10-10 2015-06-17 嵊州市诺米克进出口有限公司 Racemosins A在制备治疗或预防口腔溃疡药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
GB2222768B (en) * 1988-06-17 1992-01-22 Nat Res Dev Analgesic compounds and compositions
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
DE10299004I2 (de) * 1990-10-15 2006-03-16 Pfizer Indolderivate
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559246A (en) 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
BR9206810A (pt) 1991-11-25 1995-10-31 Pfizer Derivados de indol
US5409941A (en) 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (es) 1992-03-05 1996-10-11 Pfizer
GB9207396D0 (en) * 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
AU670579B2 (en) 1992-04-07 1996-07-25 Pfizer Inc. Indole derivatives as 5-HT1 agonists
GB9207930D0 (en) 1992-04-10 1992-05-27 Pfizer Ltd Indoles
NZ251047A (en) 1992-04-10 1996-09-25 Pfizer Acylaminoindole derivatives and medicaments
GB9208161D0 (en) 1992-04-14 1992-05-27 Pfizer Ltd Indoles
TW251284B (es) 1992-11-02 1995-07-11 Pfizer
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5607960A (en) 1993-04-22 1997-03-04 Pfizer Inc. Indole derivatives as 5-HT1-like agonists for use in migraine
GB9317096D0 (en) 1993-08-17 1993-09-29 Pfizer Ltd Indoles
DE69413240T2 (de) 1993-08-31 1999-02-04 Pfizer 5-arylindolderivate
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420503D0 (en) 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9424471D0 (en) 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis

Also Published As

Publication number Publication date
ES2167465T3 (es) 2002-05-16
CZ285633B6 (cs) 1999-10-13
ATE210980T1 (de) 2002-01-15
DE69524780T2 (de) 2002-06-13
CO4480025A1 (es) 1997-07-09
WO1996011685A3 (en) 1996-08-15
CN1160347A (zh) 1997-09-24
IL115530A0 (en) 1996-05-14
PL319868A1 (en) 1997-09-01
JPH09511755A (ja) 1997-11-25
JP3096306B2 (ja) 2000-10-10
PT785781E (pt) 2002-04-29
US20030055098A1 (en) 2003-03-20
FI971527A (fi) 1997-04-11
ZA958557B (en) 1997-04-11
CA2202484C (en) 2001-12-18
US6455567B1 (en) 2002-09-24
WO1996011685A2 (en) 1996-04-25
CA2202484A1 (en) 1996-04-25
AU3699795A (en) 1996-05-06
HUT77317A (hu) 1998-03-30
FI971527A0 (fi) 1997-04-11
PE47296A1 (es) 1996-11-12
JP2000080036A (ja) 2000-03-21
EP0785781A2 (en) 1997-07-30
BR9504375A (pt) 1997-04-08
NO971606L (no) 1997-04-08
CZ111897A3 (cs) 1998-06-17
DK0785781T3 (da) 2002-03-18
KR970705992A (ko) 1997-11-03
GB9420529D0 (en) 1994-11-30
DE69524780D1 (de) 2002-01-31
EP0785781B1 (en) 2001-12-19
IL115530A (en) 2001-03-19
NO971606D0 (no) 1997-04-08

Similar Documents

Publication Publication Date Title
IL160028A (en) Thiophene carboxamide derivatives, process for their preparation, pharmaceutical compositions comprising them and their use in therapy
AU2002359164A8 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MX9702732A (es) Uso de derivados de indol para el tratamiento de diferentes enfermedades.
HUP0402422A2 (hu) Deuterizált szubsztituált pirazolil-benzolszulfonamid-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
CA2321547A1 (en) Indole derivatives and medicinal compositions containing the same
YU12003A (sh) Novi derivati aminocikloheksana
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
NO982863L (no) Nye forbindelser med analgetisk effekt
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
AU6418296A (en) Aromatic acid diamides with antigastrin activity, a method for their preparation and their pharmaceutical use
NO307406B1 (no) Anvendelse av 1-aryl-3-(4-piperidyl)-indolderivater ved behandling av kognitive forstyrrelser
CA2431100A1 (en) Dihydroindole and tetrahydroquinoline derivatives
ECSP951549A (es) Nuevo procedimiento de tratamiento
BG106209A (en) Therapeutic agents
WO2001008667A3 (en) 2-aminotetralin derivatives for the therapy of glaucoma
RU97108290A (ru) Использование производных индола для лечения различных заболеваний, новый способ лечения
HK1097548A1 (en) Novel indeno
NO20042881L (no) Substituerte cykloheksan-derivater
BG104162A (en) Pharmaceutical composition active in the reduction of the mcp-1 protein production
MX9800916A (es) Uso de aminoacidos basicos y derivados para disminuir los niveles de ceramida.